Health and Healthcare

What to Expect When Pfizer Reports Tuesday

Wikimedia Commons

Pfizer Inc. (NYSE: PFE) is scheduled to release its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters call for $0.74 in earnings per share (EPS) and $13.31 billion in revenue. The same period of last year reportedly had EPS of $0.67 and revenue of $12.9 billion.

Earlier this summer, the company announced that it would be committing over half a billion dollars to its venture capital arm. Essentially the firm intends to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle.

Additionally, Pfizer will extend its leadership as a venture capital investor with an expanded team that leverages expertise across venture capital investing, business development, drug discovery and clinical development.

As for the plan, Pfizer Ventures will seek to invest roughly 25% of its available capital ($150 million) in promising early-stage neuroscience companies. Ultimately Pfizer will be able to support a broad array of early neuroscience research and product development opportunities, which are critical in this nascent area of science.

Over the past 52 weeks, Pfizer has outperformed the broad markets with its stock up about 16%. In just 2018 alone, the stock is up only 6%.

A few analysts weighed in on Pfizer ahead of the report:

  • BMO Capital Markets has a Buy rating and a $42 price target.
  • Cantor Fitzgerald has a Buy rating with a $45 price target.
  • Jefferies has a Hold rating with a $39 price target.
  • Credit Suisse has a Neutral rating with a $39 target.
  • Morgan Stanley has a Buy rating and a $43 target price.
  • Societe General has a Neutral rating with a $39 target.

Shares of Pfizer were last seen at $38.61, with a consensus analyst price target of $39.80 and a 52-week trading range of $32.32 to $39.43.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

 

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.